Latest news with #Veradigm
Yahoo
3 days ago
- Business
- Yahoo
Veradigm Launches Smart Medicine Podcast to Explore the Evolution of Healthcare
Podcast supports company's mission to transform health insightfully, offering expert perspectives and proven strategies to help improve outcomes and reduce costs CHICAGO, June 05, 2025--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today launched the Smart Medicine Podcast, hosted by renowned podcaster and orthopedic surgeon, Dr. Scott Sigman. The show will provide insights and inspiration for clinicians along with other healthcare professionals, as well as payer and life science industry leaders striving to navigate the complexities of modern medicine through incremental insight. The podcast features expert guests including physicians, entrepreneurs, business leaders, and healthcare innovators – who will share their journeys, discuss challenges, and reveal the strategies that enable them to thrive. Through in-depth discussions, Smart Medicine will explore how providers are leveraging both time-tested and emerging strategies to enhance patient care, optimize business operations, and shape the future of healthcare. Future episode topics will include value-based care, medical entrepreneurship, point of care innovation, clinical and operational workflow practice management, revenue cycle management, patient and staff engagement and satisfaction, the impact of government and regulation on private practice, and the business of healthcare. "By highlighting the real-world challenges, stakes, and rewards of these innovations, Smart Medicine will serve as a trusted guide for those navigating the intersection of medicine and business," said Ray Joske, VP of Marketing at Veradigm. "Each episode will follow an inspirational arc, spotlighting the obstacles overcome, the lessons learned, and the transformative impact of doing healthcare right." Dr. Sigman is a nationally and internationally recognized leader in opioid-sparing surgery, with over 25 years of clinical experience as an orthopedic surgeon specializing in knee and shoulder procedures. Widely respected in professional education and medical device development, he has authored numerous peer-reviewed publications, and his TEDx talk on the evolution of the opioid crisis has been widely acclaimed within the industry. His podcast The Ortho Show became a go-to source for the latest in orthopedic news, growing to reach more than 8,000 listeners monthly, with more than 250 episodes. Click here to listen to new episodes of Smart Medicine. About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube. © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved. View source version on Contacts Investors: Jenny Media: Amanda Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
3 days ago
- Business
- Business Wire
Veradigm Launches Smart Medicine Podcast to Explore the Evolution of Healthcare
CHICAGO--(BUSINESS WIRE)-- Veradigm ® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today launched the Smart Medicine Podcast, hosted by renowned podcaster and orthopedic surgeon, Dr. Scott Sigman. The show will provide insights and inspiration for clinicians along with other healthcare professionals, as well as payer and life science industry leaders striving to navigate the complexities of modern medicine through incremental insight. The podcast features expert guests including physicians, entrepreneurs, business leaders, and healthcare innovators – who will share their journeys, discuss challenges, and reveal the strategies that enable them to thrive. Through in-depth discussions, Smart Medicine will explore how providers are leveraging both time-tested and emerging strategies to enhance patient care, optimize business operations, and shape the future of healthcare. Future episode topics will include value-based care, medical entrepreneurship, point of care innovation, clinical and operational workflow practice management, revenue cycle management, patient and staff engagement and satisfaction, the impact of government and regulation on private practice, and the business of healthcare. 'By highlighting the real-world challenges, stakes, and rewards of these innovations, Smart Medicine will serve as a trusted guide for those navigating the intersection of medicine and business,' said Ray Joske, VP of Marketing at Veradigm. 'Each episode will follow an inspirational arc, spotlighting the obstacles overcome, the lessons learned, and the transformative impact of doing healthcare right.' Dr. Sigman is a nationally and internationally recognized leader in opioid-sparing surgery, with over 25 years of clinical experience as an orthopedic surgeon specializing in knee and shoulder procedures. Widely respected in professional education and medical device development, he has authored numerous peer-reviewed publications, and his TEDx talk on the evolution of the opioid crisis has been widely acclaimed within the industry. His podcast The Ortho Show became a go-to source for the latest in orthopedic news, growing to reach more than 8,000 listeners monthly, with more than 250 episodes. Click here to listen to new episodes of Smart Medicine. About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube. © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.
Business Wire
20-05-2025
- Business
- Business Wire
Veradigm Recognized with KLAS 2025 Points of Light Award for Optimizing Value-Based Care
CHICAGO--(BUSINESS WIRE)-- Veradigm ® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, along with Metroplex Medical Centres and one of the largest healthcare payer organizations in the country, received a 2025 KLAS Points of Light Award. The case study titled, 'Optimizing Value-Based Care by Delivering Insights at the Point of Care,' showcased how Veradigm and the payer integrated alerts into Metroplex Medical Centres' electronic health record (EHR) to help improve clinical decision support, reduce healthcare provider burnout, advance patient care, and lower overall healthcare costs. Closing quality care gaps is critical in improving patient care and health outcomes, but the information is often delivered in fragmented, external systems. This was the case for Metroplex Medical Centres, a Texas-based healthcare organization, which had two designated employees that used seven different systems to pull data on quality care gaps. The inefficient workflows - including lack of timely, actionable data - resulted in care gaps going unaddressed and time intensive administrative processes creating a fragmented physician user experience and subsequently, increased burnout. 'Like many healthcare organizations around the country, we are always looking to collaborate with the most innovative companies to help us deliver quality care to our growing patient population amidst evolving industry standards,' said Sneha Patel, MPAS, PA-C, Chief Executive Officer at Metroplex Medical Centres. 'Veradigm helped increase transparency into our gaps in care, all while helping us reduce administrative burnout and increase staff efficiency, creating a winning formula for everyone we serve.' Working together to reduce friction and improve workflows, Veradigm and the payer organization collaborated to integrate four types of real-time risk and quality alerts into Metroplex's EHRs. Key outcomes detailed in the case study show that through the collaboration, the healthcare entity was able to reduce the time spent searching for data by about 20 hours per week. The time savings has helped foster a smoother transition to value-based care, which is top of mind for ambulatory care practices. Additionally, the improved care quality led to a reduction in unnecessary emergency department visits for patients, ultimately improving patient health outcomes and lowering costs for the healthcare industry. 'To move value-based care forward, collaboration among payers and providers is critical. At Veradigm, we're focused on creating dynamic solutions, including Veradigm Payer Insights, to share patient data across the key pillars of healthcare through trusted, integrated workflows,' said Megan Zakrewsky, Vice President of Product for Clinical Data Exchange Payer Solutions at Veradigm. 'Through the Veradigm Network, we're continuing to prioritize opportunities to innovate, such as consolidating external insights by including social determinants of health and the transition of care alerts into streamlined workflows to simultaneously improve patient outcomes and reduce administrative burdens and costs.' The KLAS Points of Light award recognizes successful collaborations between payers, providers, and healthcare technology companies that have led to improvements in patient experience, cost reduction, and efficiency gains for the healthcare industry. Veradigm and the payer organization are presenting their award-winning case study at the KLAS K2 Collaboration Summit in Salt Lake City today. The session, titled 'Leveling the Playing Field,' will spotlight how the companies are working together to empower independent providers with the same high-quality payer insights typically reserved for large health systems, and how Veradigm uniquely supports providers in capturing the necessary documentation for these conditions. Click here to read the full case study. About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube. © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.
Business Wire
12-05-2025
- Health
- Business Wire
Veradigm Advances GLP-1 Real-World Evidence Generation with AI-Driven EHR Data Curation
CHICAGO--(BUSINESS WIRE)-- Veradigm ® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today an advancement in the use of artificial intelligence (AI) to scale the generation of real-world evidence (RWE) for GLP-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide. By applying AI to electronic health record (EHR) deidentified data within the Veradigm Network, researchers can now surface rich, contextual insights—such as side effects, discontinuation reasons, and social determinants of health (SDoH)—that traditionally required intensive manual curation. 'AI-powered curation allows us to unlock clinically meaningful insights from millions of patient records—insights that have traditionally been hidden in unstructured and semi-structured fields of EHR systems." -Stuart Green, SVP & GM Veradigm Life Sciences Share GLP-1 therapies are transforming the management of type 2 diabetes and obesity, yet significant gaps remain in understanding real-world usage, especially in identifying reasons for discontinuation or capturing side effects hidden in physician notes. Veradigm's AI-driven approach enables scalable extraction of clinical signals from unstructured data, offering life science organizations deeper, real-time insight into patient experiences and outcomes. 'AI-powered curation allows us to unlock clinically meaningful insights from millions of patient records—insights that have traditionally been hidden in unstructured and semi-structured fields of EHR systems,' said Stuart Green, SVP & General Manager, Veradigm Life Sciences. 'This is especially critical for GLP-1 therapies, where understanding why patients discontinue, or which side effects matter most can significantly improve patient outcomes and therapeutic strategy.' Key Capabilities and Insights from Veradigm's AI-Driven Curation Include: Discontinuation Drivers – Automatically extracts reasons for stopping therapy (e.g., side effects, cost, perceived inefficacy) from clinician notes Side Effects Monitoring – Detects and stratifies severity of gastrointestinal and side effects, such as gallbladder issues or psychiatric symptoms, through contextual analysis of progress notes Off-Brand Use Identification – Flags mentions of compounded or unapproved formulations (e.g., 'semaglutide from weight-loss clinic'), supporting safety and market surveillance Outcome Tracking – Tracks comorbidities (e.g., cardiovascular events) and treatment responses not typically captured in structured EHR fields Social and Behavioral Context – Surfaces SDoH that influence adherence and health outcomes This new offering leverages the national footprint of Veradigm Network EHR Data, capturing both structured and unstructured data across diverse patient populations and geographies. By pairing AI with clinical validation, Veradigm ensures data accuracy and applicability for life science research, regulatory engagement, and value-based decision-making. Veradigm will present a research poster based on this data at ISPOR 2025 during Poster Session 2 on Wednesday, May 14, from 4:00–7:00 PM EDT. The poster will focus on GLP-1 persistence and the real-world reasons for therapy discontinuation. To learn more, view the poster abstract. About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube. © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.
Yahoo
24-04-2025
- Business
- Yahoo
Veradigm interim CEO to leave company
This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Veradigm's interim CEO will leave the company after a little more than a year in the chief executive role, the health IT company said in a securities filing Tuesday. Tom Langan will step down on July 31. The company has begun a search to find a permanent CEO, and Langan declined to participate as a candidate in the process, Veradigm said in the filing. The health IT firm also extended its employment agreement with interim CFO Lee Westerfield through the end of the year. Langan has been a company leader at Veradigm, formerly named Allscripts, since 2018. He also served as the firm's president and chief commercial officer. Langan will receive $1.4 million, his base salary for the year plus a target annual bonus, as well as $406,000 based on performance and reimbursement of attorneys' fees for negotiating the separation agreement, according to the securities filing. A Veradigm spokesperson declined to comment on why Langan is leaving the company, or if there's an estimate as to when the CEO search process could be complete. Langan's departure serves as another leadership shakeup for Veradigm. He started as interim CEO in June last year, about six months after the board asked for and received resignations from the company's previous chief executive and chief financial officers. At that time, the company had been struggling for months to file financial reports due to 'internal control failures,' which eventually led to Veradigm being delisted from Nasdaq in early 2024. After the company was removed from the stock exchange, the firm explored strategic alternatives like a sale or a merger, but Veradigm ended its review early this year without a deal. However, the health IT company has recently made progress on its delayed financial reports. Last month, Veradigm issued its full year report for 2022, as well as restated filings for 2020, 2021 and the first three quarters of 2022. Before the release, Veradigm hadn't reported its annual or quarterly financials to regulators since November 2022. The health IT vendor also released unaudited financial ranges for 2023 and 2024, and guidance for 2025 in March. However, executives said last month Veradigm likely won't be current on its financial reporting until sometime in 2026. Recommended Reading Veradigm releases long-awaited financial results Sign in to access your portfolio
